The clinical complications of coronary artery atherosclerosis remain the leading killer in Western society. The transition from an atherosclerotic plaque to an acute coronary syndromeÐthe mechanisms linking the pathology with the clinical presentationÐis a complex and poorly understood area. Coronary atherosclerosis may present as a diverse range of coronary syndromes (angina pectoris, unstable angina, acute myocardial infarction and sudden life-threatening arrhythmia), and it will be important to identify causes of individual processes contributing to each syndrome or speci®c disease 1 . For example, there are several mechanisms that may contribute to acute myocardial infarction. The concept that acute myocardial infarction results when a plaque ruptures and leads to thrombosis may be too simple, since it has become clear that in some individuals without symptoms there is rupture of atherosclerotic plaques. What causes plaque rupture in an individual? Why do only some instances of plaque rupture lead to acute thrombosis and clinical symptoms? An understanding of the processes that regulate these events has far-reaching implications for diagnostics and therapeutics. It is important to unravel the molecular and cellular pathways that cause the primary lesions in atherosclerosis, the mechanisms that may precipitate clinical symptoms and how to detect and modify these. This is an area wherè translational research'Ðlinking fundamental cellular processes to the whole clinical pictureÐis of paramount importance.`Coronary artery disease: from bench to bedside' a symposium held at The Royal Society of Medicine followed this theme by bringing together scientists and clinicians involved in the challenge of understanding how coronary atherosclerosis leads to clinical disease.
PATHOLOGY OF ATHEROSCLEROSIS
The atherosclerotic plaque can no longer be seen as a static impediment to blood¯ow. Rather it is a dynamic lesion that may be either lipid-rich or ®brous, and contain variable amounts of smooth muscle cells and lipid-laden macrophages (foam cells). The different plaque types are related to different clinical manifestations: the lipid-rich plaque with a thin ®brous cap is more prone to plaque rupture, whereas the ®brous plaque may conform more to the traditional view of the plaque as a ®xed obstruction. Whilst a large ®brous plaque may be the cause of stable angina, the more friable lipid-rich plaque may be the one that precipitates acute syndromes. The relationship between these two extremes of plaque type and the role of in¯ammation and other factors in initiating transition from one type to another is a topic of great research interest 2 .
The initial phases of atherosclerosis seem to involve accumulation of lipoprotein particles in the intima. In animal models after a few weeks of a pro-atherogenic diet, monocytes adhere to the endothelium and migrate into the vessel wall. The processes underlying cellular rolling, adhesion and migration have been discussed in great detail elsewhere and will not be considered further here 3 . Once in the vessel wall the monocytes differentiate into macrophages, take up the lipoproteins and become foam cells. In many lesions smooth muscle cells migrate into the intima and subsequent secretion of matrix leads to the development of the ®brous plaque.
Monocytes/macrophages
Monocytes and macrophages are at the heart of the atherosclerotic lesion and de®nition of the molecular physiology of these cells has basic importance for understanding plaque biology. Two so-called scavenger receptors, type A (SRA) and CD36, appear to be of importance in the ability of macrophages to take up oxidized and modi®ed low-density lipoproteins (LDLs)Ðthe process by which they turn into foam cells 4±6 . SRA is highly conserved throughout evolution and its normal physiological role is unde®ned. However, mice lacking the gene for SRA or CD36 seem resistant to developing atherosclerosis 7, 8 . This suggests a fundamental role for these receptors, at least in murine models. Cellular models have shown that macrophage phenotype can be modulated by altering the intercellular amount of soluble scavenger receptor to inhibit the uptake of oxidized LDL and prevent foam cell formation. Modulating the expression of soluble scavenger receptor expression may reduce the formation of foam cells in experimental atherosclerosis. This can be achieved by manipulation of the transcription factor peroxisome proliferator activated receptor g 9, 10 . Drugs that act through this transcription factor are already in clinical use (e.g. the glitazones) and it would be interesting to know whether these effects also occur in humans.
The smooth muscle cell in atherosclerosis
The second major cellular constituent of atherosclerotic plaque is smooth muscle cells. Whilst excessive smooth muscle cell proliferation is evident in plaques, paradoxically there is also increased vascular smooth muscle cell death 11 . Subclinical plaque rupture and healing occur continuously, and vascular smooth muscle cells and the extracellular matrix they produce are important in the healing process. There are numerous mitogenic stimuli present in the local environment in plaques, but smooth muscle cells isolated from vulnerable plaques show reduced rates of cell division, and are more susceptible to signals that promote programmed cell death (apoptosis). Enzymes that regulate or stimulate apoptosis (e.g. caspases) are expressed to a high degree in atherosclerotic plaques and, in isolated cell systems, incubation of smooth muscle cells with leukocytes or monocytes causes smooth muscle cell death by apoptosis. This may resemble a local in¯ammatory state, with cells of the immune system releasing mediators that promote vascular smooth muscle cell death, thereby thinning the cover of the lipid core. Overall the smooth muscle phenotype found in unstable plaques seems unsuited to the task of plaque repair and healing, and this may predispose to plaque rupture 12 .
INFLAMMATION AND ATHEROSCLEROSIS
The basic cell biology of the plaque points towards in¯ammation as a fundamental mechanism underlying plaque development and instability 3 . There are immunological interactions between the macrophages and T-lymphocytes within the plaque. Early in plaque formation T lymphocytes adhere to the endothelium, and blockade of this response can decrease atherogenesis in animal models. Furthermore, the interaction of the adhesion molecule CD40 with its ligand CD40LÐa reaction that was initially described as a part of the immune reaction of T and B cellsÐresults in the production of in¯ammatory cytokines and changes in matrix formation 13 . Loss of CD40L appears to result in smaller more ®brous lesions, and animals lacking g-interferon (derived from T cells) show reduced atherogenesis. g-interferon decreases smooth muscle cell replication and matrix production and may therefore have a role in initiating plaque instability by weakening the plaque cap 14 . In addition T lymphocytes that express CD25 (the IL-2 receptor) are found in increased number in plaques from unstable coronary syndromes 15 . Thus immune cells, including T and B lymphocytes, seem to be involved in atherogenesis and plaque destabilization. Which are the signals that might stimulate or enhance an in¯ammatory response in the vessel wall? Much interest has focused on modi®ed low-density lipoprotein as an in¯ammatory stimulus, but recently infectious organisms have also been implicated. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus have been found within plaques but it is unclear whether these have a causal role or are innocent bystanders brought to the plaque by immune cells.
Infection or in¯ammation?
Epidemiological studies have identi®ed an association between systemic markers of chronic infection/in¯ammation and atherosclerosis. C. pneumoniae and H. pylori have been linked with coronary atherosclerosisÐeither because they were detected within atherosclerotic plaques or because serological studies showed an excess of infection with these agents in patients with coronary atherosclerosis. However, many of these studies were in small numbers with poorly matched groups. A recent meta-analysis, and data from two large studies, did not demonstrate an association between C. pneumoniae infection and the future risk of coronary disease 16 . However, studies based on serology should be interpreted with caution since this will not readily distinguish between recent and distant infection, or periods of reactivation, and the timing of infection or chronicity of infection could be important factors. Work in murine models indicates that certain infectious agents, including herpesviruses, can greatly enhance atherogenesis, provided the animals are infected at the right time 17 . These studies offer the ®rst direct proof that chronic infections can be causal, at least in animal models. Despite the negative results for individual organisms in humans, there is good evidence that markers of low-grade in¯ammation such as Creactive protein and serum amyloid A protein are associated with future risk of coronary disease 18 .
ENDOTHELIUM AND INFECTION/INFLAMMATION
Clearly the endothelium plays a critical role in atherogenesis and in¯ammation is an important process in atherogenesis. Recent evidence indicates that in¯ammation can impair certain endothelial functions in a manner similar to conventional cardiovascular risk factors 19 . For example, local or systemic in¯ammation greatly impairs endothelium-dependent relaxation in humans 20, 21 . Indeed the degree of impairment is greater than that caused by hypertension, diabetes or hypercholesterolaemia. The implications of this for disease are not yet clear, but a loss of endothelium-derived nitric oxide would be expected to promote cellular adhesion and plaque development. 
Gene transfer
Whilst greater understanding will lead to new targets for conventional small-molecule therapeutics, an alternative approach has emerged in the form of gene therapy. Interest in gene therapy initially centred on single gene defects, but it has become clear that gene transfer to provide transient gene expression may be useful in other situations; the gene may be considered as a pro-drug delivering the active agent to an appropriate site. The technical challenges of vascular gene therapy include appropriate targeting of gene delivery, the regulation of cellular uptake and control of gene expression. In the vasculature, several candidate genes have emerged and studies in animals have employed nitric oxide synthase genes, growth-factor or anti-growth-factor genes and many others. However, the area is probably most advanced for vascular endothelial growth factor (VEGF), an agent that stimulates blood vessel growth but which can also increase endothelial nitric oxide generation and reduce neointima formation in animal models. Although VEGF DNA has been injected into humans as naked DNA, better delivery systems will be needed to test the potential for this agent in clinical trials 22 . One possibility would be to deliver the gene to the outside of the vessel wall. In such a system, the VEGF gene gets expressed in the vessel wall and produces effects which may have therapeutic bene®t. Clearly there is some way to go before the therapeutic potential of gene transfer can be assessed in the clinic, but in many ways the vasculature looks a good system in which to explore this potential.
Gene manipulation
An alternative approach would be to manipulate the expression of endogenous genes. This may be possible by targeting transcription factors that regulate the expression of multiple genes involved in a coordinated physiological responseÐEhrlich's magic bullet, in¯uencing multiple targets with a single shot. The key to this will be to determine which transcription factors regulate speci®c genes in speci®c tissues. With the application of gene array technology it should be possible to determine which genes are switched on by speci®c physical or chemical signals, or in response to the disease process itself. Manipulation of transcription factors that control gene expression may be superior to gene therapy in that it could target dysregulation of genes in tissues where the cellular machinery is already primed. Erg 1 is a transcriptional factor that may be used to modulate gene expression selectively in vivo because it is an injuryresponsive transcription factor and therefore able to modulate gene expression at areas of vessel injuryÐfor example, injury induced by shear forces 23 .
NOVEL DIAGNOSTICS
Whilst discoveries in basic science hold the promise of new therapeutics, one area in which there have been major advances of direct clinical relevance is in the development of imaging techniques. It is already possible to provide accurate three-dimensional imaging of the cardiac chambers and great vessels with magnetic resonance imaging (MR), and, with the anticipated improvements in resolution, MR angiography may provide non-invasive (and radiation-free) de®nition of coronary anatomy. In animals at least, it is already possible to de®ne lipid-rich unstable plaques, and the ability both to delineate anatomy and to characterize plaque composition in patients would be a major advance 24, 25 . At present invasive imaging of coronary arteries by intravascular ultrasound provides the clearest imaging of the atherosclerotic plaque in human coronary arteries, but this is unlikely to be of routine diagnostic use. Future technological improvements, including miniaturized MRI, may allow in vivo assessment of plaque cell biology and characterization of the potentially unstable plaque. Furthermore, the use of chemically`caged' contrast media that are liberated from the cage by speci®c enzymes raises the possibility of allowing selective visualization of areas of the vessel wall where these enzymes are most activeÐfor example, to identify areas of increased apoptotic activity. The ability to assess function of the coronary circulation as well as anatomy makes these techniques increasingly powerful tools. Basic advances in vascular biology continue apace. With the increased power of genomics, which was not covered at the RSM meeting, it seems clear that new diagnostics and therapeutics will emerge. The key seems to be the accurate functional characterization of atheroma, so that the most vulnerable plaques can be stabilized.
